Ramaish Sharma , Zuber Khan , Sidharth Mehan , Ghanshyam Das Gupta , Acharan S. Narula
{"title":"Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons","authors":"Ramaish Sharma , Zuber Khan , Sidharth Mehan , Ghanshyam Das Gupta , Acharan S. Narula","doi":"10.1016/j.mrrev.2024.108518","DOIUrl":null,"url":null,"abstract":"<div><div>Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, primarily impairs upper and lower motor neurons, leading to debilitating motor dysfunction and eventually respiratory failure, widely known as Lou Gehrig's disease. ALS presents with diverse symptomatology, including dysarthria, dysphagia, muscle atrophy, and hyperreflexia. The prevalence of ALS varies globally, with incidence rates ranging from 1.5 to 3.8 per 100,000 individuals, significantly affecting populations aged 45–80. A complex interplay of genetic and environmental factors underpins ALS pathogenesis. Key genetic contributors include mutations in chromosome 9 open reading frame 72 (<em>C9ORF72</em>), superoxide dismutase type 1 (<em>SOD1</em>), <em>Fused</em>in sarcoma (<em>FUS</em>), and TAR DNA-binding protein (<em>TARDBP</em>) genes, accounting for a considerable fraction of both familial (fALS) and sporadic (sALS) cases. The disease mechanism encompasses aberrant protein folding, mitochondrial dysfunction, oxidative stress, excitotoxicity, and neuroinflammation, contributing to neuronal death. This review consolidates current insights into ALS's multifaceted etiology, highlighting the roles of environmental exposures (e.g., toxins, heavy metals) and their interaction with genetic predispositions. We emphasize the polygenic nature of ALS, where multiple genetic variations cumulatively influence disease susceptibility and progression. This aspect underscores the challenges in ALS diagnosis, which currently lacks specific biomarkers and relies on symptomatology and familial history. Therapeutic strategies for ALS, still in nascent stages, involve symptomatic management and experimental approaches targeting molecular pathways implicated in ALS pathology. Gene therapy, focusing on specific ALS mutations, and stem cell therapy emerge as promising avenues. However, effective treatments remain elusive, necessitating a deeper understanding of ALS's genetic architecture and the development of targeted therapies based on personalized medicine principles. This review aims to provide a comprehensive understanding of ALS, encouraging further research into its complex genetic underpinnings and the development of innovative, effective treatment modalities.</div></div>","PeriodicalId":49789,"journal":{"name":"Mutation Research-Reviews in Mutation Research","volume":"794 ","pages":"Article 108518"},"PeriodicalIF":6.4000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mutation Research-Reviews in Mutation Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1383574224000310","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, primarily impairs upper and lower motor neurons, leading to debilitating motor dysfunction and eventually respiratory failure, widely known as Lou Gehrig's disease. ALS presents with diverse symptomatology, including dysarthria, dysphagia, muscle atrophy, and hyperreflexia. The prevalence of ALS varies globally, with incidence rates ranging from 1.5 to 3.8 per 100,000 individuals, significantly affecting populations aged 45–80. A complex interplay of genetic and environmental factors underpins ALS pathogenesis. Key genetic contributors include mutations in chromosome 9 open reading frame 72 (C9ORF72), superoxide dismutase type 1 (SOD1), Fusedin sarcoma (FUS), and TAR DNA-binding protein (TARDBP) genes, accounting for a considerable fraction of both familial (fALS) and sporadic (sALS) cases. The disease mechanism encompasses aberrant protein folding, mitochondrial dysfunction, oxidative stress, excitotoxicity, and neuroinflammation, contributing to neuronal death. This review consolidates current insights into ALS's multifaceted etiology, highlighting the roles of environmental exposures (e.g., toxins, heavy metals) and their interaction with genetic predispositions. We emphasize the polygenic nature of ALS, where multiple genetic variations cumulatively influence disease susceptibility and progression. This aspect underscores the challenges in ALS diagnosis, which currently lacks specific biomarkers and relies on symptomatology and familial history. Therapeutic strategies for ALS, still in nascent stages, involve symptomatic management and experimental approaches targeting molecular pathways implicated in ALS pathology. Gene therapy, focusing on specific ALS mutations, and stem cell therapy emerge as promising avenues. However, effective treatments remain elusive, necessitating a deeper understanding of ALS's genetic architecture and the development of targeted therapies based on personalized medicine principles. This review aims to provide a comprehensive understanding of ALS, encouraging further research into its complex genetic underpinnings and the development of innovative, effective treatment modalities.
肌萎缩侧索硬化症(ALS)是一种进行性神经退行性疾病,主要损害上下运动神经元,导致衰弱的运动功能障碍,最终导致呼吸衰竭,被广泛称为卢伽雷氏病。渐冻人症的症状多种多样,包括构音障碍、吞咽困难、肌肉萎缩和反射亢进。肌萎缩性脊髓侧索硬化症在全球的发病率各不相同,发病率为每 10 万人 1.5 至 3.8 例,主要影响 45-80 岁的人群。肌萎缩侧索硬化症的发病机理是遗传和环境因素的复杂相互作用。主要的遗传因素包括第 9 号染色体开放阅读框 72(C9ORF72)、1 型超氧化物歧化酶(SOD1)、Fusedin 肉瘤(FUS)和 TAR DNA 结合蛋白(TARDBP)基因的突变,在家族性(fALS)和散发性(sALS)病例中均占相当大的比例。该病的发病机制包括蛋白质折叠异常、线粒体功能障碍、氧化应激、兴奋毒性和神经炎症,从而导致神经元死亡。本综述整合了目前对 ALS 多方面病因的见解,强调了环境暴露(如毒素、重金属)的作用及其与遗传倾向的相互作用。我们强调了 ALS 的多基因性质,即多种基因变异累积影响疾病的易感性和进展。这一方面凸显了 ALS 诊断所面临的挑战,目前 ALS 诊断缺乏特定的生物标志物,只能依赖症状学和家族病史。ALS 的治疗策略仍处于初级阶段,包括对症治疗和针对与 ALS 病理有关的分子通路的实验方法。针对特定 ALS 基因突变的基因疗法和干细胞疗法是很有希望的途径。然而,有效的治疗方法仍然难以捉摸,这就需要对 ALS 的基因结构有更深入的了解,并根据个性化医疗原则开发针对性疗法。本综述旨在提供对 ALS 的全面了解,鼓励进一步研究其复杂的遗传基础,并开发创新、有效的治疗方法。
期刊介绍:
The subject areas of Reviews in Mutation Research encompass the entire spectrum of the science of mutation research and its applications, with particular emphasis on the relationship between mutation and disease. Thus this section will cover advances in human genome research (including evolving technologies for mutation detection and functional genomics) with applications in clinical genetics, gene therapy and health risk assessment for environmental agents of concern.